ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SIEN Sientra Inc

0.174
0.00 (0.00%)
After Hours
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sientra Inc NASDAQ:SIEN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.174 0.1668 0.1816 0 01:00:00

Sientra to Report Third Quarter 2019 Financial Results on November 7, 2019

17/10/2019 9:05pm

GlobeNewswire Inc.


Sientra (NASDAQ:SIEN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Sientra Charts.

Sientra, Inc. (Nasdaq: SIEN), a medical aesthetics company, announced today that it will release financial results for the third quarter 2019 after the close of trading on Thursday, November 7, 2019. Sientra will host a conference call to discuss financial results the same day at 5:00 p.m. Eastern Time.

The dial-in numbers are 844-464-3933 for domestic callers and 765-507-2612 for international callers. The conference ID is 9194103.

A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com. The webcast will be archived on the website following completion of the call. 

About Sientra

Headquartered in Santa Barbara, California, Sientra is a diversified global medical aesthetics company and a leading partner to aesthetic physicians. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s Breast Products Segment includes its OPUS™ breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology,  and BIOCORNEUM® the #1 performing, preferred and recommended scar gel of plastic surgeons(*). The Company’s miraDry Segment comprises its miraDry® system, which is approved for sale in over 40 international markets, and is the only non-invasive FDA-cleared device for the permanent reduction of underarm sweat, odor and hair of all colors.____________________(*) Data on file

Investor Relations
805-679-8885

1 Year Sientra Chart

1 Year Sientra Chart

1 Month Sientra Chart

1 Month Sientra Chart

Your Recent History

Delayed Upgrade Clock